df2755a

DF2755A is a novel synthetic small molecule drug that acts as a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2. It selectively inhibits neutrophil chemotaxis induced by CXCR1/2 ligands without affecting the binding affinity of CXCL8 (IL-8) to these receptors. The compound demonstrates favorable oral pharmacokinetics and has shown efficacy in reducing inflammatory and post-operative pain in preclinical models. It also reduces neutrophil recruitment and IL-1β production in vivo. DF2755A is considered a potential therapeutic option for inflammatory pain, post-operative pain, chemotherapy-induced peripheral neuropathy, and interstitial cystitis/bladder pain syndrome[1][3][6].

Other names

(2S)-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid (IUPAC)sodium salt of the above for pharmaceutical use